<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982354</url>
  </required_header>
  <id_info>
    <org_study_id>2019-KOE-003</org_study_id>
    <nct_id>NCT04982354</nct_id>
  </id_info>
  <brief_title>Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia</brief_title>
  <official_title>A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Health South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baptist Health South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study designed to identify the effect of daunorubicin-cytarabine liposome&#xD;
      (CPX-351) in combination with a FLT3-inhibitor (midostaurin) as induction and consolidation&#xD;
      therapy for patients with high-risk FLT3 mutated acute myeloid leukemia (AML) and subsequent&#xD;
      CD34+-selected allogeneic stem cell transplant from HLA compatible related or unrelated&#xD;
      donors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2031</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the complete remission rate</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>Assess the complete remission rate following induction therapy with CPX-351 plus midostaurin when administered to patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Progression Free Survival (PFS)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>to determine the PFS of these patients following allo SCT. To estimate PFS the Kaplan-Meier method will be used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Overall Survival (OS)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>to determine the OS of these patients following allo SCT. To estimate OS the Kaplan-Meier method will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the rate of Minimal Residual Disease (MRD) negativity</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>Ascertain the rate of MRD negativity by next generation sequencing at sequential time post following induction treatment at complete remission prior to allo Stem Cell Transplantation (SCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Minimal Residual Disease (MRD)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
    <description>Correlation of duration of MRD negative status with duration of complete remission of these patients will be assessed using Spearman's correlation with reported p value.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daunorubicin-cytarabine liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) Induction Therapy followed by Busulfan/Melphalan/Fludarabine Conditioning therapy and CD34+-selected allografts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>For this trial, patients will be treated with CPX-351 100 (daunorubicin 44 mg/m2 and cytarabine 100 mg/m2) for 3 doses on days 1, 3 and 5 of one and on days 1 + 3 of a second cycle of induction therapy, depending on response obtained following the first induction. Thereafter, up to 2 cycles of consolidation therapy of 2 doses on days 1 and 3 of daunorubicin 29 mg/m2 and cytarabine 65 mg/m2 will be administered to the patients.</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>The FLT3 directed inhibitor, midostaurin, will be given at a dose of 50mg twice daily, starting on day 8 through day 21 of each cycle of CPX-351 until admission for allogeneic stem cell transplant.</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <other_name>Rydapt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>0.8 mg/kg/dose every six hours x 12 doses administered intravenously</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>70 mg/m2/day x 2 doses administered intravenously</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>25 mg/m2/day x 5 doses administered intravenously</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor</intervention_name>
    <description>Allogeneic stem cell transplant infused intravenously</description>
    <arm_group_label>Investigational Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have a Karnofsky (adult) Performance Status of at least 70%.&#xD;
&#xD;
          -  Patients must have adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are pregnant or breast-feeding&#xD;
&#xD;
          -  Active viral, bacterial or fungal infection&#xD;
&#xD;
          -  Patient seropositive for Human Immunodeficiency Virus (HIV-I /II); Human T-Cell&#xD;
             Lymphotrophic Virus (HTLV -I /II)&#xD;
&#xD;
          -  Presence of leukemia in the Central Nervous System (CNS).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Koehne, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Cancer Institute at Baptist Health of South Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guenther Koehne, MD, PhD</last_name>
    <phone>786-596-2000</phone>
    <email>GuentherK@Baptisthealth.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health of South Florida</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://baptisthealth.net/cancer-care/home</url>
    <description>Miami Cancer Institute Website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

